Earnings Call Summary | Pulse Biosciences(PLSE.US) Q2 2024 Earnings Conference
Earnings Call Summary | Pulse Biosciences(PLSE.US) Q2 2024 Earnings Conference
The following is a summary of the Pulse Biosciences Inc. (PLSE) Q2 2024 Earnings Call Transcript:
以下是Pulse Biosciences Inc.（pulse biosciences）2024年第二季度業績會議電話簡報摘要：
Financial Performance:
金融業績：
Pulse Biosciences reported cash and cash equivalents totaling $26.2 million as of June 30, 2024, compared to $58.7 million the previous year.
The company noted a total GAAP cost increase of $1.5 million to $11.7 million for Q2 2024, primarily driven by non-cash stock-based compensation.
Received $60 million in gross proceeds from a rights offering which closed in July 2024, not included in the reported cash balance.
截至2024年6月30日，Pulse Biosciences報告現金及現金等價物總計2620萬美元，相比上年的5870萬美元有所減少。
該公司註明，由於非現金股票補償的主要推動，2024年Q2的總GAAP成本增加了150萬美元，達到了1170萬美元。
從在2024年7月結束的配股中獲得了6000萬美元的募集總收益，該金額未計入報告的現金餘額。
Business Progress:
業務進展：
Completed first US soft tissue ablation cases under FDA clearance and received breakthrough device designation for a cardiac surgical system.
Expanded leadership team and moved headquarters to Miami, Florida.
Plans to initiate pivotal clinical trials for soft tissue ablation and a surgical system for atrial fibrillation in early 2025.
通過FDA的審批，完成了美國首例軟組織消融手術，同時還獲得了一種用於心臟手術的突破性設備認定。
擴充領導團隊並將總部遷至佛羅里達州邁阿密市。
計劃在2025年初啓動軟組織消融和房顫手術系統的關鍵性臨床試驗。
More details: Pulse Biosciences IR
更多詳情請參見Pulse Biosciences IR。
Tips: For more comprehensive details, please refer to the IR website. The article is only for investors' reference without any guidance or recommendation suggestions.
提示：如需更全面的詳情，請參閱投資人關係網站。本文僅供投資者參考，不作任何指引或建議。
譯文內容由第三人軟體翻譯。